Pfizer's stock (PFE) has seen considerable fluctuation recently, though it appears to be stabilizing around $25 as institutions begin to buy in. Despite a dip following reports of a US probe into the timing of their
COVID-19 vaccine results, analysis of the stocks' recent performance compared to other pharmaceutical stocks shows a potential for rebound.
Analysts remain optimistic about Pfizer, with some describing it as the most undervalued S&P 500 or biotech stock available. Pfizer's strong
institutional backing and high dividend yield contribute to this perception. Criticism of the company hasn't been absent, however, including a Senator accusing Pfizer of the 'biggest tax-dodging scheme in pharma history.' The
Q4 earnings have been well-received, with even Jim Cramer remaining optimistic. The company's future outlook to 2025 appears 'marginally encouraging' according to reports. Despite these challenges and controversies, the perception remains that Pfizer is a solid investment, particularly for those looking for
value and dividends.
Pfizer Stocks News Analytics from Wed, 09 Oct 2024 07:00:00 GMT to Fri, 28 Mar 2025 20:00:31 GMT -
Rating 0
- Innovation 2
- Information 5
- Rumor -1
